Advanced RA Therapies
Advanced-treatment use by drug class did not significantly differ across the four primary target groups at baseline, year 1, or year 2. The study's advanced-treatment population consisted of patients receiving biologics or JAK inhibitors.
1 sources - 3 claims
Advanced-treatment use by drug class did not significantly differ across the four primary target groups at baseline, year 1, or year 2. The study's advanced-treatment population consisted of patients receiving biologics or JAK inhibitors.